HCPCS Code J9042: Brentuximab Vedotin, 1 mg

Learn how HCPCS Code J9042 is billed for brentuximab vedotin (Adcetris) injection, 1 mg, including coding details for Medicare and oncology claims.

Use Code

## **What is HCPCS Code J9042?** HCPCS code J9042 is designated for “Injection, brentuximab vedotin, 1 mg.” This code falls under the category of chemotherapy drugs and is maintained by the Centers for Medicare & Medicaid Services (CMS). It provides essential coding information for billing and reimbursement of injectable oncology therapies. Brentuximab vedotin, marketed under the brand name Adcetris, is an antibody–drug conjugate directed against CD30-expressing cells. It is FDA-approved for the treatment of several lymphoma subtypes, including classical Hodgkin lymphoma, systemic anaplastic large cell lymphoma, certain peripheral T-cell lymphoma variants, and primary cutaneous anaplastic large cell lymphoma. It is also used in some instances of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, and has been explored in broader oncology contexts such as renal cell cancer. The drug may be used in combination with chemotherapy as first-line therapy for advanced-stage (III or IV) classical Hodgkin lymphoma, or as a single agent for relapsed or refractory disease. Brentuximab vedotin is administered by intravenous infusion, and its use must be supported by documentation of the patient’s diagnosis and underlying condition. In oncology practice, it is sometimes applied in cases where malignancy presents with uncertain behavior, requiring careful coding and clinical justification. Developed by Seagen Inc. (formerly Seattle Genetics) in collaboration with Takeda Pharmaceutical, brentuximab vedotin has been billed under HCPCS Code J9042 since its effective date of January 1, 2013. The code ensures standardized reporting and reimbursement of this injectable chemotherapy drug across Medicare and commercial insurance programs.

## **HCPCS code J9042 documentation requirements** HCPCS Code J9042 (Injection, brentuximab vedotin, 1 mg) documentation requirements typically include thorough medical records that support the use of the drug. Documentation should contain: ### **Medical necessity** Documentation for J9042 must establish why brentuximab vedotin is medically necessary. The record should include a confirmed diagnosis of a CD30-expressing lymphoma within FDA-approved indications, along with relevant patient history such as prior therapies, response, or intolerance. ### **Treatment rationale** The provider’s notes should explain the clinical rationale for prescribing brentuximab vedotin, showing how it fits the patient’s condition and treatment plan. If required, a Letter of Medical Necessity may be included to summarize history, pathology, and justification for therapy. ### **Dosage and administration** The exact dose prepared and administered must be recorded in milligrams, with billing units reflecting the “1 unit = 1 mg” rule. Documentation should specify the route of administration (intravenous infusion), start and stop times when applicable, and any drug waste. ### **Coding support** Medical records must support the ICD-10-CM diagnosis codes linked to the claim, along with the correct CPT and HCPCS codes. Modifiers may apply to the HCPCS code when drug waste occurs and must be supported by clear chart documentation. ### **Authorization and compliance** If the payer requires prior authorization, the approval number and details must be documented. For hospital outpatient claims, the appropriate revenue code (commonly 0636, but payer dependent) should also be supported in the record. Documentation must provide a complete picture of medical necessity, treatment delivery, and compliance with CMS and payer requirements.

## **J9042 billing requirements** The billing requirements for HCPCS code J9042 (Injection, brentuximab vedotin, 1 mg) include: ### **Units and claims reporting** Billing for J9042 is based on the exact amount administered, with one billing unit equal to one milligram of brentuximab vedotin. For example, a 50 mg vial given to the patient should be billed as 50 units. ### **Administration codes** Claims must also include the correct CPT code for chemotherapy infusion or injection, since payers generally require both the drug and the administration service. ### **Modifiers** Medicare requires the use of modifiers for single-dose vials. The JW modifier must be used when part of the vial is discarded, while the JZ modifier is required when no drug is discarded. ### **NDC and payer rules** Some payers require reporting of the National Drug Code (NDC) with the correct unit of measure and quantity. Providers should verify payer-specific requirements for NDC submission, coverage, and reimbursement rules. ### **Revenue codes** For hospital outpatient billing, J9042 must be paired with the correct revenue code, most often 0636 for drugs requiring detailed coding, though requirements may vary by payer.

## **Other relevant codes** - **J9045** - Injection, carboplatin, 50 mg - **J9299** - Injection, nivolumab, 1 mg - **J9271** - Injection, pembrolizumab, 1 mg

Frequently asked questions

HCPCS code J9042 represents the injection of brentuximab vedotin, 1 mg, a chemotherapy drug used for treating certain types of lymphoma.

Brentuximab vedotin is used to treat Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and other CD30-expressing lymphomas. It targets cancer cells expressing the CD30 protein.

ADCetris (brentuximab vedotin) is an antibody-drug conjugate that combines targeted immunotherapy with a chemotherapy agent, functioning as a targeted chemotherapy.

Yes, vedotin refers to the chemotherapy component monomethyl auristatin E (MMAE) linked to the antibody in brentuximab vedotin, which disrupts microtubules in cancer cells to inhibit their growth.